Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): PR Newswire
  • Source:
    PR Newswire US. 11/08/2021.
  • Additional Information
    • Alternate Title:
      ALLERGAN-AAO-data
    • Subject Terms:
      Illinois
    • Abstract:
      NORTH CHICAGO, Ill., Nov. 8, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, announced that it will present new pooled post-hoc analyses and patient-reported outcomes (PROs) of VUITYTM (pilocarpine HCl ophthalmic solution) 1.25%, newly approved by the FDA as the first and only eye drop to treat presbyopia; additional analyses on DURYSTA® (bimatoprost intracameral implant); and three real-world data studies on the glaucoma patient journey at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting, November 12-15. [ABSTRACT FROM PUBLISHER]